Amgen Inc. $AMGN Stock Holdings Raised by Faithward Advisors LLC

Faithward Advisors LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9,549.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 132,492 shares of the medical research company’s stock after purchasing an additional 131,119 shares during the period. Amgen makes up about 6.2% of Faithward Advisors LLC’s investment portfolio, making the stock its largest holding. Faithward Advisors LLC’s holdings in Amgen were worth $46,617,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Dogwood Wealth Management LLC increased its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Anfield Capital Management LLC lifted its stake in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Amgen during the 4th quarter valued at about $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen in the fourth quarter worth approximately $33,000. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AMGN shares. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Argus reduced their price objective on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Wells Fargo & Company raised their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $354.42.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by insiders.

Amgen Trading Up 0.7%

Shares of Amgen stock opened at $347.01 on Wednesday. Amgen Inc. has a 1-year low of $269.01 and a 1-year high of $391.29. The company’s fifty day simple moving average is $340.42 and its 200-day simple moving average is $345.87. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a market capitalization of $187.28 billion, a PE ratio of 24.15, a P/E/G ratio of 3.46 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the business posted $4.90 EPS. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.